Lipocine (LPCN) Director Michael Grissinger Receives 2,000-Share Award

What Happened

• Michael Grissinger, a director of Lipocine Inc. (LPCN), was granted 2,000 shares as an award on August 3, 2026. The award is recorded at $2.11 per share for a total value of $4,220. This was an award/acquisition (derivative grant), not an open-market purchase.

Key Details

• Transaction date: 2026-08-03; reported on Form 4 filed 2026-08-07 (filing appears late relative to the 2-business-day rule).
• Instrument/type: Award/Grant (derivative acquisition), transaction code A.
• Price/value: $2.11 per share; total reported value $4,220.
• Shares owned after transaction: Not specified in the provided filing.
• Vesting: Subject to vesting — 1/3 vests on Aug 3, 2027; remaining 2/3 vest monthly over the following two years (see footnote).

Context

• This was a restricted/share award subject to multi-year vesting, not an immediate market purchase or sale, so it does not represent an instant cash investment or disposition.
• The grant is relatively small in dollar terms; such awards are commonly part of director compensation. The late filing may be reportable to the SEC and is worth noting for disclosure timing but does not by itself indicate trading intent.